Compare Biogen Inc (BIIB) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Tractor Supply Co — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Tractor Supply Co trades at $35.42 (market cap $18.39B). The key difference: Biogen Inc is the larger of the two by market cap, and Tractor Supply Co pays a 2.72% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TSCO | |
|---|---|---|
Market Cap | $30.13B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $62.65 |
52-Week Low | $128.93 | $29.14 |
Enterprise Value | $37.20B | $24.70B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
TSCO trades at $36.45, up 5.29% on the day, with a bullish technical signal and strong profitability metrics including a 39.51% ROE. Recent earnings have missed expectations, but the company maintains stable revenue growth and announced strategic initiatives like pet assortment expansion and seasonal events to drive engagement.
The outlook is mixed: valuation appears reasonable with a P/E of 18.38, and insider buying signals confidence, but near-term headwinds include soft discretionary demand and cost pressures. Risks involve execution of turnaround efforts amid economic sensitivity, while analyst consensus leans neutral with a $36.29 price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
